These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

367 related items for PubMed ID: 19074171

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Clinical effects and safety of rituximab for treatment of refractory pediatric autoimmune diseases.
    El-Hallak M, Binstadt BA, Leichtner AM, Bennett CM, Neufeld EJ, Fuhlbrigge RC, Zurakowski D, Sundel RP.
    J Pediatr; 2007 Apr; 150(4):376-82. PubMed ID: 17382113
    [Abstract] [Full Text] [Related]

  • 26. Residual inflammation after rituximab treatment is associated with sustained synovial plasma cell infiltration and enhanced B cell repopulation.
    Teng YK, Levarht EW, Toes RE, Huizinga TW, van Laar JM.
    Ann Rheum Dis; 2009 Jun; 68(6):1011-6. PubMed ID: 18647852
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Rituximab induces a rapid and sustained remission in Colombian patients with severe and refractory systemic lupus erythematosus.
    Pinto LF, Velásquez CJ, Prieto C, Mestra L, Forero E, Márquez JD.
    Lupus; 2011 Oct; 20(11):1219-26. PubMed ID: 21784778
    [Abstract] [Full Text] [Related]

  • 34. Outcome of protein-losing gastroenteropathy in systemic lupus erythematosus treated with prednisolone and azathioprine.
    Mok CC, Ying KY, Mak A, To CH, Szeto ML.
    Rheumatology (Oxford); 2006 Apr; 45(4):425-9. PubMed ID: 16234272
    [Abstract] [Full Text] [Related]

  • 35. [Long-term follow-up of patients with refractory systemic lupus erythematosus during rituximab treatment].
    Tsanian MÉ, Solov'ev SK, Torgashina AV, Aleksandrova EN, Radenska-Lopovok SG, Nikolaeva EV, Khrennikova IaB, Nasonov EL.
    Ter Arkh; 2014 Apr; 86(5):40-9. PubMed ID: 25026801
    [Abstract] [Full Text] [Related]

  • 36. Assessment of flares in lupus patients enrolled in a phase II/III study of rituximab (EXPLORER).
    Merrill J, Buyon J, Furie R, Latinis K, Gordon C, Hsieh HJ, Brunetta P.
    Lupus; 2011 Jun; 20(7):709-16. PubMed ID: 21478286
    [Abstract] [Full Text] [Related]

  • 37. Anti B-cell therapy against refractory thrombocytopenia in SLE and MCTD patients: long-term follow-up and review of the literature.
    Jovancevic B, Lindholm C, Pullerits R.
    Lupus; 2013 Jun; 22(7):664-74. PubMed ID: 23612795
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. A case of refractory vasculitic ulcers in a systemic lupus erythematosus patient responding to rituximab and hyperbaric oxygen therapy.
    Lui NL, Thumboo J, Fong KY.
    Int J Rheum Dis; 2009 Dec; 12(4):366-9. PubMed ID: 20374378
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.